Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

Add OXBDF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/16/2019 5:24:47 PM - Followers: 7 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
Trades In UK as (OXB.L)
Company website

UK company traded on grey's in US


Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#728   Yes George, JD says that more deals are marcusl2 03/16/19 05:24:46 PM
#727   Marcus, Thank you!!! georgejjl 03/15/19 11:05:03 PM
#726   https://seekingalpha.com/article/4248943-oxford-biomedicas-oxbdf-ceo-john-dawson marcusl2 03/15/19 09:40:55 AM
#725   Oxford Biomedica announces R&D collaboration with Microsoft to georgejjl 03/12/19 07:24:26 PM
#724   A MUST READ REGARDING TODAY'S NEWS!!! georgejjl 03/11/19 07:23:07 PM
#723   Data on Parkinson Disease Gene Therapy, AXO-Lenti-PD, Anticipated georgejjl 02/22/19 03:10:17 PM
#722   Dosed second patient in the SUNRISE-PD phase 2 georgejjl 02/22/19 01:10:46 PM
#721   FDA confirmed that studies previously conducted using firs georgejjl 02/12/19 08:12:16 PM
#720   First two patients dosed in SUNRISE-PD phase 2 georgejjl 02/12/19 08:05:01 PM
#719   Could this possibly be a $15 billion deal cfoofme 12/29/18 05:45:29 PM
#718   CAR-T stocks georgejjl 12/26/18 11:31:18 AM
#717   Doubling Down on Gene Therapies, Novartis Buys CellforCure georgejjl 12/22/18 09:47:02 AM
#716   Novartis, still struggling with Kymriah manufacturing, is providing georgejjl 12/18/18 06:56:29 PM
#715   Safety and Efficacy of OXB-202, a Genetically Engineered georgejjl 12/15/18 05:09:10 PM
#714   Oxford BioMedica to capture 25-30% of lentiviral vector marcusl2 12/10/18 03:21:00 PM
#713   (This is VERY interesting) marcusl2 12/10/18 03:20:33 PM
#711   Oxford Biomedica PLC Axovant FDA meeting feedback marcusl2 12/06/18 04:07:44 PM
#710   I agree George, but along with a few marcusl2 12/02/18 02:11:02 PM
#709   Novartis could buyout Oxford BioMedica georgejjl 12/01/18 04:40:40 PM
#708   Oxford BioMedica notes the longer-term analyses from pivotal georgejjl 12/01/18 03:27:20 PM
#707   Possible ways forward for Car T 5T4 combinations ? marcusl2 11/25/18 04:59:39 AM
#706   “Any new therapy is going to start in marcusl2 11/25/18 04:12:25 AM
#705   Scott Gottlieb, M.D. marcusl2 11/25/18 04:11:37 AM
#704   Digital tech from Autolus and Oxford BioMedica to marcusl2 11/22/18 11:41:18 AM
#703   Looking good. marcusl2 11/22/18 04:50:58 AM
#702   W. Buffett marcusl2 11/21/18 06:07:53 AM
#701   https://twitter.com/EWhiteheadFdn/status/1064918865786884097 marcusl2 11/20/18 01:46:18 PM
#700   Discussion The results of a Phase I/II clinical trial georgejjl 11/18/18 12:24:02 PM
#699   https://twitter.com/mwl471/status/1063371272120348672 marcusl2 11/16/18 05:17:24 AM
#698   Oxford BioMedica marcusl2 11/14/18 10:01:26 AM
#697   Edison Report regarding Oxford BioMedica georgejjl 11/09/18 08:26:37 PM
#696   OXB-102 trial georgejjl 11/07/18 09:04:55 PM
#695   Yes I am very optimistic George. marcusl2 10/30/18 04:46:17 AM
#694   Sheila Roy is a true pioneer for ProSavin georgejjl 10/30/18 01:29:12 AM
#693   Oxford BioMedica notes that Axovant doses first patient georgejjl 10/30/18 01:10:40 AM
#692   “The millions of patients with Parkinson’s disease globally marcusl2 10/25/18 08:03:42 AM
#691   The London, United Kingdom-based company plans to raise marcusl2 10/25/18 08:02:33 AM
#690   BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- marcusl2 10/16/18 04:22:15 AM
#689   See page 13 georgejjl 10/15/18 10:09:34 PM
#688   Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced georgejjl 10/05/18 01:05:09 PM
#687   Orchard Therapeutics plans $172.5 million U.S. IPO georgejjl 10/05/18 08:33:15 AM
#686   Good news. Orchard should be quite a valuable marcusl2 10/05/18 05:38:52 AM
#685   CART-19 before Oxford Biomedica georgejjl 10/02/18 09:14:10 PM
#684   Last, but not least, RetinoStat has been developed georgejjl 09/19/18 08:17:55 PM
#683   Wet AMD marcusl2 09/18/18 04:02:53 AM
#682   All animals treated with 1×10^7 total T georgejjl 09/17/18 11:33:34 PM
#681   Long-term follow up of a phase 1/2 study georgejjl 09/17/18 11:21:08 PM
#680   Stuart, finances for Axo-Lenti-PD pretty spectacular. Firmly believe marcusl2 09/13/18 04:43:34 PM
#679   Fast forward to 1:01:57 to listen to our marcusl2 09/06/18 04:34:32 PM